

SEQUENCE LISTING

- 5 (1) GENERAL INFORMATION:
- (i) APPLICANT: Vassilios Papadopoulos
Martine Culty
- (ii) TITLE OF INVENTION: Peripheral-type Benzodiazepine Receptor:
10 A Tool for Detection, Diagnosis, Prognosis, and Treatment of Cancer
- (iii) NUMBER OF SEQUENCES: 3
- (iv) CORRESPONDENCE ADDRESS:
- 15 (A) ADDRESSEE: Pratt & Associates, Inc.
(B) STREET: 10821 Hillbrooke Lane
(C) CITY: Potomac
(D) STATE: MARYLAND
(E) COUNTRY: USA
20 (F) ZIP: 20854
- (v) COMPUTER READABLE FORM:
- (A) MEDIUM TYPE: Floppy disk
(B) COMPUTER: Apple Macintosh
25 (C) OPERATING SYSTEM: Macintosh 7.5
(D) SOFTWARE: Microsoft Word 6.0
- (vi) CURRENT APPLICATION DATA:
- (A) APPLICATION NUMBER:
30 (B) FILING DATE:
(C) CLASSIFICATION:
- (vii) PRIOR APPLICATION DATA:
- (A) APPLICATION NUMBER: 09/047652
35 (B) FILING DATE: March 25, 1998
- (viii) ATTORNEY/AGENT INFORMATION:
- (A) NAME: Sana A. Pratt
(B) REGISTRATION NUMBER: 39,441
40 (C) REFERENCE/DOCKET NUMBER: 009/116/SAP
- (ix) TELECOMMUNICATION INFORMATION
- (A) TELEPHONE: (301)294-9171
45 (B) TELEFAX: (301)294-7357
- (2) INFORMATION FOR SEQ ID NO:1:
- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 652 base pairs
50 (B) TYPE: Nucleic acid
(C) STRANDEDNESS: Single

(D) TOPOLOGY: Linear

(ii) SEQUENCE DESCRIPTION: SEQ ID NO:1:

5	CCACGGCGAA GGTCTCCGCT GGTACGCCGG CCTGCAGAAG	40
	CCCTCGTGGC ACCCGCCCCA CTGGGTGCTG GGCCCTGTCT	80
	GGGGCACGCT CTACTCAGCC ATGGGGTACG GCTCCTACCT	120
	GGTCTGGAAA GAGCTGGGAG GCTTCACAGA GAAGGCTGTG	160
	GTTCCCCTGG GCCTCTACAC TGGGCAGCTG GCCCTGAACT	200
10	GGGCATGGCC CCCCATCTTC TTTGGTGCCC GACAAATGGG	240
	CTGGGCCTTG GTGGATCTCC TGCTGGTCAG TGGGGCGGCG	280
	GCAGCCACTA CCGTGGCCTG GTACCAGGTG AGCCCGCTGG	320
	CCGCCCCGCT GCTCTACCCC TACCTGGCCT GGCTGGCCTT	360
	CACGACCACA CTCAACTACT GCGTATGGCG GGACAACCAT	400
15	GGCTGGCGTG GGGGACGGCG GCTGCCAGAG TGAGTGCCCCG	440
	GCCCACCAGG GACTGCAGCT GCACCAGCAG GTGCCATCAC	480
	GCTTGTGATG TGGTGGCCGT CACGCTTTCA TGACCACTGG	520
	GCCTGCTAGT CTGTCAGGGC CTTGGCCCAG GGGTCAGCAG	560
	AGCTTCAGAG GTGGCCCCAC CTGAGCCCCC ACCCGGGAGC	600
20	AGTGTCTGT GCTTTCTGCA TGCTTAGAGC ATGTTCTTGG	640
	AACATGGAAT TT	652

(3) INFORMATION FOR SEQ ID NO:2:

(i) SEQUENCE CHARACTERISTICS:

25	(A) LENGTH: 652 base pairs
	(B) TYPE: Nucleic acid
	(C) STRANDEDNESS: Single
	(D) TOPOLOGY: Linear

(ii) SEQUENCE DESCRIPTION: SEQ ID NO:2:

	CCACGGCGAG GGTCTCCGCT GGTACGCCGG CCTGCAGAAG	40
--	---	----

	CCCTCGTGGC	ACCCGCCCCA	CTGGGTGCTG	GGCCCTGTCT	80
	GGGGCACGCT	CTACTCAGCC	ATGGGGTACG	GCTCCTACCT	120
	GGTCTGGA	GAGCTGGGAG	GCTTCACAGA	GAAGGCTGTG	160
	GTTCCCCTGG	GCCTCTACAC	TGGGCAGCTG	GCCCTGAACT	200
5	GGGCATGGCC	CCCCATCTTC	TTTGGTGCCC	GACAAATGGG	240
	CTGGGCCTTG	GTGGATCTCC	TGCTGGTCAG	TGGGGCGGCG	280
	GCAGCCACTA	CCGTGGCCTG	GTACCAGGTG	AGCCCGCTGG	320
	CCGCCCCGCT	GCTCTACCCC	TACCTGGCCT	GGCTGGCCTT	360
	CACGACCACA	CTCAACTACT	GCGTATGGCG	GGACAACCAT	400
10	GGCTGGCGTG	GGGGACGGCG	GCTGCCAGAG	TGAGTGCCCG	440
	GCCCACCAGG	GA	CTGCAGCT	GCACCAGCAG	480
	GCTTG	TGATG	TGGTGCCGT	CACGCTTTCA	520
	GCCTGCTAGT	CTGTCAGGGC	CTTGGCCCAG	GGGTCAGCAG	560
	AGCTTCAGAG	GTGGCCCCAC	CTGAGCCCCC	ACCCGGGAGC	600
15	AGTGTCCCTGT	GCTTTCTGCA	TGCTTAGAGC	ATGTTCTTGG	640
	AACATGGAAT	TT			652

(4) INFORMATION FOR SEQ ID NO:3:

20 (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 169 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: Linear

25 (ii) SEQUENCE DESCRIPTION: SEQ ID NO:3:

	Xaa	Xaa	Xaa	Xaa	Xaa	Xaa	Xaa	Xaa	Xaa	Xaa
	1				5					10
	Xaa	Xaa	Xaa	Xaa	Xaa	Xaa	Xaa	Xaa	Xaa	Xaa
30					15					20
	Xaa	Xaa	Xaa	Xaa	Xaa	Xaa	His	Gly	Glu	Gly
					25					30
35	Leu	Arg	Trp	Tyr	Ala	Gly	Leu	Gln	Lys	Pro

					35					40
	Ser	Trp	His	Pro	Pro	His	Trp	Val	Leu	Gly
					45					50
5	Pro	Val	Trp	Gly	Thr	Leu	Tyr	Ser	Ala	Met
					55					60
10	Gly	Tyr	Gly	Ser	Tyr	Leu	Val	Trp	Lys	Glu
					65					70
	Leu	Gly	Gly	Phe	Thr	Glu	Lys	Ala	Val	Val
					75					80
15	Pro	Leu	Gly	Leu	Tyr	Thr	Gly	Gln	Leu	Ala
					85					90
	Leu	Asn	Trp	Ala	Trp	Pro	Pro	Ile	Phe	Phe
					95					100
20	Gly	Ala	Arg	Gln	Met	Gly	Trp	Ala	Leu	Val
					105					110
25	Asp	Leu	Leu	Leu	Val	Ser	Gly	Ala	Ala	Ala
					115					120
	Ala	Thr	Thr	Val	Ala	Trp	Tyr	Gln	Val	Ser
					125					130
30	Pro	Leu	Ala	Ala	Arg	Leu	Leu	Tyr	Pro	Tyr
					135					140
	Leu	Ala	Trp	Leu	Ala	Phe	Thr	Thr	Thr	Leu
					145					150
35	Asn	Tyr	Cys	Val	Trp	Arg	Asp	Asn	His	Gly
					155					160
40	Trp	Arg	Gly	Gly	Arg	Arg	Leu	Pro	Glu	
					165					

45